Company Announcement, Helsinki, 22 December 2023 at 3 PM (EET)
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") corrects the company announcement released by the Company on 21 December 2023 at 4 PM (EET) regarding the Company’s financial information in 2024 and updated disclosure policy. In all language versions of the release, the date of the Annual General Meeting was incorrect. The corrected announcement can be read below.
“Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces that it will publish the following financial information in 2024:
The 2023 Financial Statements Release and Half-Yearly Report July−December 2023 (H2) on Tuesday, February 27, 2024. Half-Yearly Report January-June 2024 (H1) on Friday, August 16, 2024.
Nexstim’s Annual Report 2023 will be published and available on the Company’s website on Wednesday, March 6, 2024.
The Annual General Meeting is tentatively scheduled to be held on Thursday March 28, 2024, at 10:00 am.
The Company also announces that due to the delisting of the secondary listing of the Company’s shares on Nasdaq First North Growth Market Sweden on April 15, 2023, the Company will implement an updated disclosure policy as of January 1, 2024. Following the update of the disclosure policy, the Company will publish information only in Finnish and English.
The updated disclosure policy is attached to this announcement and will be available on the Company’s website at www.nexstim.com/investors/corporate-governance on January 1, 2024.”
NEXSTIM PLC
Mikko Karvinen, CEO
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com
The Company’s Certified Advisor is Carnegie Investment Bank AB (publ).
Nexstim Plc_Disclosure policy_01.01.2024_EN
Nexstim Plc_Disclosure policy_01.01.2024_FI
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com